News & Information

Solutions provide sponsors greater control and consistency when radiation therapy is part of the clinical trial protocol.

Clario, a leading provider of endpoint data solutions to the clinical trials industry, has expanded its oncology trial support by collaborating with Radialogica to offer enhanced quality control for radiation therapy (RT). This new capability helps sponsors ensure radiation is delivered consistently and according to protocol across global sites, improving trial integrity and the reliability of safety and efficacy outcomes.

As radiation therapy continues to play an important role in modern oncology trials, sponsors are increasingly looking for ways to reduce variability and strengthen oversight. Through this collaboration, Clario now offers centralized, expert-led review of RT plans and treatment delivery, covering both concurrent and prior radiotherapy, to support oncology studies through its comprehensive imaging services.

“With radiation therapy, small inconsistencies can create major impacts on trial outcomes,” said Anu Bansal, M.D., Vice President, Imaging, Oncology at Clario. “By integrating radiation QA into our offering, we’re giving sponsors more confidence in their data and more control over how protocol-driven care is delivered across sites.”

Since 1972, Clario’s endpoint data solutions have supported more than 30,000 clinical trial opportunities, including 5,000+ in oncology, at every phase of drug development with regulatory-grade evidence, advanced imaging science, and operational excellence. The addition of radiation QA further strengthens Clario’s ability to help sponsors navigate complex protocols involving multiple treatment modalities.

Radialogica brings extensive experience in radiation oncology and a proven track record of delivering independent, centralized quality review in both clinical and trial settings. Their services are now available as part of Clario’s oncology imaging solutions, offering sponsors a single, expert-led partner for all trial imaging and RT oversight needs.

“We’re proud to be working with Clario to help sponsors achieve greater standardization and confidence in radiation planning and delivery,” said Andrew C. Cowen, Chief Executive Officer at Radialogica. “This collaboration aligns with our shared mission of supporting high-quality, patient-focused cancer research.”

This offering was developed in response to increasing sponsor requests for centralized RT quality control and reflects Clario’s commitment to evolving alongside sponsor needs, while continuing to ensure scientific and operational rigor.